Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,362 across all filing types
Latest filing 2022-08-30 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业集团股份有限公司关于召开2022年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2022 half-year performance explanation meeting (业绩说明会) for investors. It references the previously published 2022 half-year report but does not contain the report itself or detailed financial data. The document provides information on the meeting time, location, participants, and how investors can participate and ask questions. It is essentially an invitation and informational notice about an upcoming investor presentation event rather than the presentation or report itself. Therefore, it fits best under the category of Investor Presentation (IP) as it focuses on the company's financial results and interaction with investors regarding those results.
2022-08-30 Chinese
亚宝药业集团股份有限公司第八届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the eighth meeting of the eighth board of directors of 亚宝药业集团股份有限公司. It includes approval of the 2022 half-year report, salary determinations for the chairman and general manager, and voting results. The document is short (675 characters) and primarily reports on board decisions and approvals rather than containing the full half-year financial report itself. It also includes details about the board meeting and voting outcomes. This fits the category of Board/Management Information (MANG), as it announces board meeting resolutions and management compensation decisions. It is not the full interim report (IR), nor is it a simple announcement of a report publication (RPA).
2022-08-22 Chinese
亚宝药业集团股份有限公司2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 半年度报告摘要' which translates to '2022 Half-Year Report Summary'. It contains financial data comparing the current reporting period to the previous year, including total assets, net profit, earnings per share, and shareholder information. The document explicitly states it is a half-year report summary and references the full half-year report for detailed information. The content includes substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. The document length is 2560 characters, which is relatively short but contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-22 Chinese
亚宝药业集团股份有限公司2022年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "2022 年半年度报告" which translates to "2022 Semi-Annual Report". It covers the period from January 1, 2022 to June 30, 2022, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data, management discussion and analysis, company overview, business segments, and operational details. It explicitly states it is an unaudited half-year report and contains comprehensive financial and operational information. This matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), and it is the report itself, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. H1 2022
2022-08-22 Chinese
亚宝药业集团股份有限公司关于参与投资杭州华方丰柏投资管理合伙企业（有限合伙）的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement by 亚宝药业集团股份有限公司 regarding its investment in a limited partnership fund called 杭州华方丰柏投资管理合伙企业（有限合伙）. It includes extensive information about the investment amount, the partnership agreement, the partners involved, financial data of related entities, rights and obligations of partners, investment scope, management, risk disclosures, and the impact on the company. The document is not a financial report like an annual or interim report, nor is it a regulatory filing or a simple announcement of a report. It is an announcement about a capital investment transaction by the company into a fund, describing the terms and conditions of the investment and related risks. Therefore, it fits best into the category of Capital/Financing Update (CAP). The document length (over 12,000 characters) and detailed content support this classification with high confidence.
2022-08-19 Chinese
亚宝药业集团股份有限公司关于参与设立的投资基金完成私募投资基金备案的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 亚宝药业集团股份有限公司 regarding the completion of the private equity fund registration for an investment fund they participated in establishing. It includes details about the fund, its management, registration date, and related information. The document is short (1038 characters) and serves as an announcement of a financing-related event (private equity fund registration). It does not contain financial statements, audit information, or detailed financial results. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-07-26 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.